Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder (MDD), as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.